Maintenance infliximab for Crohn's disease [2] (multiple letters)

Lancet

Volumn 360, Issue 9345, 2002, Pages 1602-1603

  Cottone, Mario ^a   Orlando, Ambrogio ^a   Casà, Angelo ^a   Oliva, Lorenzo ^a   Hanauer, Stephen B ^b  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

CANCER; CLINICAL MEDICINE; COLON; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; ENTERITIS; HEPATOBILIARY DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPHOMA; MAINTENANCE DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RISK;

EID: 0037121248     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(02)11538-8     Document Type: Letter

References (1)

1. JD Lewis WB Bilker C Brenseinger JJ Deren DJ Vaughn BL Strom Inflammatory bowel disease is not associated with an increased risk of lymphoma Gastroenterology 121 2001 1080 1087